Innovation is at the heart of Celixir. Our unique technology platform drives in-house discovery and manufacturing. We have more than 20 tissue-specific regenerative medicines in our pipeline, which is unprecedented in the field of regenerative medicine.

Pipeline

At Celixir, our R&D activities are focused on bringing life-saving regenerative medicines to market.

Our first investigational cardiac regenerative medicine consists of iMP cells. iMP cells are designed to treat patients with ischaemic heart disease – ischaemic cardiomyopathy – undergoing coronary artery bypass graft (CABG). They are injected around cardiac scar tissue via a single application during bypass surgery.

Status

We have successfully completed European Phase 2 trials using iMP cells as a cardiac-specific cellular medicine. Additional trials are set to begin in 2017. iMP cells have been designated as an advanced therapeutic medicinal product by the European Medicines Agency. A Phase 2 trial in Kawasaki disease is also planned. 

Our investigational topical gel containing platelet lysate is capable of regenerating injured tendons near the surface of the skin.

Status

The topical regenerative medicine has successfully completed European Phase 2 trials in tennis elbow. A Phase 3 trial is planned to start in early 2018.

PML cells are being investigated as a treatment for patients with mild to moderate heart failure.

Status

PML cells are ready to enter European clinical trials as a treatment for patients with mild to moderate heart failure.

We are investigating the use of immunoregulatory progenitor (iRP) cells for the treatment of type 1 diabetes and immuno-onco modulatory progenitor cells (iOMP) for their use in oncology.